이번 주 새 소식 🆕 최근 업데이트
이 논문의 관계도
List view
Current PaperWhatsOverviews · Chest
Neoadjuvant / Perioperative Immunotherapy연결 근거: neoadjuvant, resectable, pathologic response
- Methods방법론 색인 — 어떤 분석을 어떤 논문이 썼나연결어: neoadjuvant, perioperative, resectable
- ReviewClinical Oncology 종합 리뷰연결어: neoadjuvant, perioperative, resectable
- Statistics통계 방법론 리뷰연결어: neoadjuvant, perioperative, resectable
- Yang 2024Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer…연결어: neoadjuvant, perioperative, resectable
- Bang 2025Perioperative Pembrolizumab for Locally Advanced Thymic Epithelial Tumors: A Single-Arm, Phase…연결어: neoadjuvant, perioperative, pathologic response
- +44 more
Extranodal Extension Imaging연결 근거: nodal
- Henson 2024Criteria for the diagnosis of extranodal extension detected on radiological imaging in head and…연결어: extranodal extension, ene, nodal
- Jang 2023Radiologic Extranodal Extension of Metastatic Lymph Nodes in Patients With Non-Small Cell Lung…연결어: extranodal extension, ene, nodal
- Jang 2023Radiologic Extranodal Extension of Metastatic Lymph Nodes in Patients With Non-Small Cell Lung…연결어: extranodal extension, ene, nodal
- Chohan 2025Pathological extranodal extension in head and neck cancer: A prognostic biomarker with therapeu…연결어: extranodal extension, ene, nodal
- ReviewBiomedical Imaging 종합 리뷰연결어: extranodal extension, ene, nodal
- +8 more
Radiomics and Radiogenomics연결 근거: radiomics, radiomic
- Methods방법론 색인 — 어떤 분석을 어떤 논문이 썼나연결어: radiomics, radiomic, radiogenomic
- ReviewBiomedical Imaging 종합 리뷰연결어: radiomics, radiomic, radiogenomic
- Statistics통계 방법론 리뷰연결어: radiomics, radiomic, radiogenomic
- Su 2023Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and t…연결어: radiomics, radiomic, radiogenomic
- Henry 2022Investigation of radiomics based intra-patient inter-tumor heterogeneity and the impact of tumo…연결어: radiomics, radiomic, subsampling
- +21 more
Thoracic CT / PET Imaging연결 근거: ct
- Methods방법론 색인 — 어떤 분석을 어떤 논문이 썼나연결어: ct, pet, pulmonary
- ReviewClinical Pulmonology 종합 리뷰연결어: ct, pet, pulmonary
- Statistics통계 방법론 리뷰연결어: ct, pet, pulmonary
- DeFreitas 2021Complications of Lung Transplantation: Update on Imaging Manifestations and Management연결어: ct, pet, pulmonary
- Cottin 2016Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)연결어: ct, pulmonary, egpa
- +64 more
Shared Tags이 논문의 tags: adjuvant, atezolizumab, chemotherapy, durvalumab, neoadjuvant
- Xiong 2025Delta-radiomics features combined with haematological index predict pathological complete respo…공유 tag: adjuvant, atezolizumab, durvalumab, neoadjuvant
- Loi 2021The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility…공유 tag: adjuvant, atezolizumab, chemotherapy, neoadjuvant
- Qu 2024Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in l…공유 tag: adjuvant, chemotherapy, neoadjuvant
- Kim 2019Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in t…공유 tag: adjuvant, chemotherapy, neoadjuvant
- Janjigian 2021Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot공유 tag: adjuvant, atezolizumab, neoadjuvant
- +73 more
최근 7일(2026-09-06 이후) 동안 추가·갱신된 것들입니다. RSS로도 구독할 수 있습니다.
추가·갱신된 논문
- 2026-09-13 · Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC A Real-World Analysis Using a Nationwide Claims Database in Japan
- 2026-09-13 · De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer
- 2026-09-13 · 2405-6308/© 2022 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the
- 2026-09-13 · Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC A Real-World Analysis Using a Nationwide Claims Database in Japan
- 2026-09-13 · Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA) A Nationwide, Real-World Study
- 2026-09-13 · Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer
- 2026-09-13 · Comparability of PD‐L1 immunohistochemistry assays for non‐small‐cell lung cancer a systematic review
- 2026-09-06 · Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
- 2026-09-06 · Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer
- 2026-09-06 · Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy PACIFIC-KR
- 2026-09-06 · Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer
- 2026-09-06 · PD-L1 Immunohistochemistry Assays for Lung Cancer Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- 2026-09-06 · consolidation therapy in patients with non-small cell lung cancer who
- 2026-09-06 · Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer
- 2026-09-06 · Brief Report Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC A Post Hoc Subgroup Analysis From PACIFIC
- 2026-09-06 · Chemo-Radio-Immunotherapy for NSCLC III ESRATS Thresholds for DLCO Correlate with Radiation Dosimetry and Pneumonitis Rate
- 2026-09-06 · Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- 2026-09-06 · Yu Wang, MD,*,# Tao Zhang, MD,*,# Yilin Huang, MS,y Wei Li, MD,* Jingjing Zhao, PhD,* Yin Yang, MD,*
- 2026-09-06 · Five-Year Survival Outcomes From the PACIFIC Trial Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- 2026-09-06 · Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
- 2026-09-06 · Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer
- 2026-09-06 · Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
- 2026-09-06 · The Eighth Edition AJCC Cancer Staging Manual Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging
- 2026-09-06 · Disclosure: Dr. Girard reports receiving research grants/support from
- 2026-09-06 · Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis
- 2026-09-06 · Challenges of Guarantee-Time Bias
- 2026-09-06 · Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression
- 2026-09-06 · Introduction to the Analysis of Survival Data in the Presence of Competing Risks
갱신된 리뷰
- 2026-09-13 · 방법론 색인 — 어떤 분석을 어떤 논문이 썼나
- 2026-09-06 · 이번 주 새 소식
새 screening 후보
> Open access 논문은 📎 Zotero에 추가 링크를 열고 브라우저의 Zotero Connector로 저장하세요.
- 2026-09-13 · The efficacy and feasibility of neoadjuvant immunochemotherapy versus chemotherapy in Limited-Stage Small-Cell lung cancer. — include
- 2026-09-13 · Treatment-free interval as a determinant of second-line chemotherapy outcomes in extensive-stage small cell lung cancer: a Dutch population-based study. — include · 📎 Zotero에 추가 (OA/hybrid)
- 2026-09-13 · PREDICT-GBM: A multicenter platform advancing personalized glioblastoma radiotherapy planning. — include · 📎 Zotero에 추가 (OA/gold)
- 2026-09-13 · Segmentation-based deep learning emphysema quantification using chest CT: improved accuracy and robustness vs LAA-950. — include
- 2026-09-13 · PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype. — include · 📎 Zotero에 추가 (PMC)
- 2026-09-13 · Artificial Intelligence-Based Assessment of Pathologic Response to Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung Cancer: An International Multicenter Cohort Study. — include · 📎 Zotero에 추가 (OA/hybrid)
- 2026-09-13 · Deep learning image reconstruction for 50-keV virtual monoenergetic dual-energy CT of the thyroid: a prospective "dual-low" dose study. — include
- 2026-09-13 · HIF1A+CSF3R+ neutrophils-dominated hypoxic niche induced metabolic reprogramming for neoadjuvant therapy resistance in NSCLC. — include · 📎 Zotero에 추가 (PMC)
- 2026-09-13 · TAMing the tumor: targeting immune inhibitory receptors on tumor-associated macrophages in pediatric brain tumors - an emerging immunotherapy strategy. — include · 📎 Zotero에 추가 (PMC)
- 2026-09-13 · Transcriptomic analysis of a phase 1 trial for intraperitoneal monocytes plus IFNs in ovarian cancer reveals support and recruitment of cell-mediated immunity. — include · 📎 Zotero에 추가 (PMC)
- 2026-09-13 · Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial. — include
- 2026-09-13 · The changing therapeutic landscape of small-cell lung cancer. — include
- 2026-09-13 · The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussion. — include
- 2026-09-06 · Spatial habitat radiomics predicts tertiary lymphoid structure status and identifies an IDO1+ migratory dendritic cell axis in breast cancer. — include · 📎 Zotero에 추가 (OA/gold)
- 2026-09-06 · Artificial intelligence-based assessment of tumor bed stroma in non-small cell lung cancer after neoadjuvant therapy: Association with pathologic response and survival. A multicenter study. — include · 📎 Zotero에 추가 (OA/hybrid)
- 2026-09-06 · Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes. — include · 📎 Zotero에 추가 (OA/hybrid)
- 2026-09-06 · Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors. — include
- 2026-09-06 · Adjuvant immunotherapy in resectable non-small cell lung cancer with nodal downstaging. — include
- 2026-09-06 · Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer. — include
- 2026-09-06 · Topogram-based anatomical labelling of CT series: anatomy-aware CT data processing using deep learning. — include · 📎 Zotero에 추가 (OA/hybrid)
- 2026-09-06 · GTPase RAB31 supports ANXA1-driven macrophage education through clathrin-mediated endocytosis to suppress antitumor immunity. — include · 📎 Zotero에 추가 (OA/gold)
- 2026-09-06 · Targeting the PD-L1-induced PDK4/GLS metabolic axis overcomes anti-PD-1 resistance in non-small cell lung cancer. — include · 📎 Zotero에 추가 (OA/gold)
- 2026-09-06 · IL20RB drives non-small cell lung cancer progression and immune evasion via K267‑dependent activation of JAK2 phosphorylation and STAT3 signaling. — include
- 2026-09-06 · MTAP loss in non-small-cell lung Cancer and beyond: Therapeutic targeting of the MAT2A-PRMT5 axis. — include
- 2026-09-06 · Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer. — include
- 2026-09-06 · Mechanistic modeling of tumor immune microenvironment reveals strategies to enhance antibody-drug conjugates' efficacy. — include · 📎 Zotero에 추가 (PMC)
- 2026-09-06 · Enhanced CD33 CAR-NK cells secreting anti-CD73scFv overcome adenosine-mediated immunosuppression and improve anti-AML efficacy. — include · 📎 Zotero에 추가 (PMC)